Cytogenetics and molecular analysis in chronic myelogenous leukemia patients treated by interferon and chemotherapy.
A new combination regimen including chemotherapy and interferon was started in 1986 for the treatment of 24 chronic myelogenous leukaemia patients in chronic phase. Complete cytogenetic remission were noted in 10 patients and 6 of them are in sustained remission. The overall survival was 70% at 40 months. However, a minimal residual disease was detected in the 3 patients tested with the polymerase chain reaction. In addition no correlation was detected between the site of the breakpoint and response to therapy.
Guilhot
F
F
Département d'Hématologie et Oncologie Médicale, Hôpital Jean-Bernard, Poitiers, France.
Ahmad
M
M
Mahon
F X
FX
Dreyfus
B
B
Brizard
A
A
Huret
J L
JL
Kitzis
A
A
Tanzer
J
J
D000328:Adult; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007370:Interferon Type I / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012074:Remission Induction / Q000379:methods
D007370:Interferon Type I; D003561:Cytarabine; D006918:Hydroxyurea